Shire Sues Nostrum Pharma Over ANDA For Epilepsy Drug

Law360, New York (January 14, 2004, 12:00 AM EST) -- U.K. drug maker Shire Pharmaceuticals Group has sued Nostrum Pharmaceuticals over its plans to produce a generic version of Shire’s epilepsy drug Carbatrol.

The lawsuit was filed in the U.S. District Court for the District of New Jersey.

Patents on Carbatrol, an anti-convulsant that generated sales of $45 million in 2002, expire in 2011 and 2019.

Shire made total drug sales of $859 million in 2002.

The lawsuit results from an Abbreviated New Drug Application(ANDA) filed by Nostrum for a generic version of the 300 mg...
To view the full article, register now.